Delving into the Latest Updates on Benoxinate Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid, 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester, Benoxinate

+ [21]

Target

SCNA

Action

modulators

Mechanism

SCNA modulators(Sodium voltage-gated channel alpha subunits modulators)

Therapeutic Areas

Eye DiseasesOther Diseases

Active Indication

Excessive tearingAnesthesia

Inactive Indication-

Originator Organization

Santen Pharmaceutical Co., Ltd.

Active Organization

Santen Pharmaceutical Co., Ltd.

ROHTO NITTEN Co., Ltd.

Shenyang Oasis Pharmaceutical Co., Ltd

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (07 Jun 1966),

Anesthesia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC17H29ClN2O3

InChIKeyPRGUDWLMFLCODA-UHFFFAOYSA-N

CAS Registry5987-82-6

The goal of this interventional comparative study is to assess the efficacy and safety of a novel regimen of preservative-free unit-dose topical anesthetics for controlling early postoperative pain following single-step transepithelial PRK surgery.
The main research questions to answer are:
Question 1: Are topical anesthetics effective in reducing post-PRK pain?
Question 2: Are short-term topical anesthetics toxic to the cornea?
Question 3: How to prevent abuse of topical anesthetics by patients at home?
Participants were planned to undergo a bilateral single-step transepithelial PRK surgery to correct their refractive errors and received a standard post-PRK treatment regimen for both eyes. Additionally, one eye was offered a preservative-free topical anesthetic as an experimental group and the other eye was offered a preservative-free artificial tear as a control group.

Start Date30 Jan 2023

Sponsor / Collaborator

Assiut University

NCT05666362

/ CompletedPhase 4IIT

Hemodynamic Response Of Premature Brain To Pain During Retinopathy Of Prematurity Screening: A Randomized Controlled Trial

Study of cerebral hemodynamic changes in preterm infant and the effect of topical anesthetic eye drops ( benoxinate hydrochloride 0.4% ) on PIPP score and cerebral hemodynamic changes during fundus examination in neonates with gestational age ≤ 34 weeks or birth weight ≤ 2.000 Kg regardless their gestational age , after postnatal day 28.

Start Date20 Jan 2023

Sponsor / Collaborator

Alexandria University

100 Clinical Results associated with Benoxinate Hydrochloride

Login to view more data

100 Translational Medicine associated with Benoxinate Hydrochloride

Login to view more data

100 Patents (Medical) associated with Benoxinate Hydrochloride

Login to view more data

565

Literatures (Medical) associated with Benoxinate Hydrochloride

31 Dec 2025·ANNALS OF MEDICINE

Optimizing injection accuracy for Baxter’s nerve entrapment: an ultrasonography-guided approach based on anatomical surface landmarks

Article

Author: Choi, Jung-woo ; Shin, Mi Young ; Kim, Sang-Hyun ; Nam, Yong-Seok ; Kim, Jun-Ho ; Kim, In-Beom ; Lee, Hyung-Jin

INTRODUCTION:

The clinical feasibility and applicability of surface landmarks for Baxter nerve entrapment to proximal and distal sites is unclear. This study provides anatomical guidelines for optimal transducer placement using two specific landmarks, the most inferior tip of the medial malleolus (A) and the most protruding posterior tip of the calcaneus (B), to enhance the diagnostic and therapeutic injection efficacy for proximal and distal entrapment sites.

MATERIALS AND METHODS:

Eighty-six feet from 45 fresh cadavers (25 male and 20 female) were dissected to determine Baxter's nerve (BN) localization. With A and B as key landmarks, distances (OB, OBN, BBN, and BNx) were measured to accurately localize the nerve. The OB distance was divided into four equal-length quadrants or zones. Twenty feet from 10 fresh cadavers (5 males and 5 females) underwent ultrasonography-guided injection using in-plane and out-of-plane techniques. Two practitioners marked the landmarks to ensure reproducibility and an experienced anesthesiologist administered the injections. The spread of the injected dye was assessed, and statistical analyses were conducted.

RESULTS:

Average OB, OBN, BBN, and BNx distances were 50.55 ± 5.83 mm, 7.19 ± 5.85 mm, 43.77 ± 5.31 mm, and 12.13 ± 5.75 mm, respectively. Significant sex-related differences (O to B; B to BN) and notable disparities between the distances on the right and left sides (O to BN; BN to X-axis) were observed. Most of the BN (81.4%) was located in zone 1, representing 25% of the OB length. For entrapment site 1, the in-plane technique achieved a 100% success rate whereas the out-of-plane method achieved an 80% success rate. For entrapment site 2, the out-of-plane approach (90% success) outperformed the in-plane approach (20% success).

CONCLUSION:

Using two specific landmarks provides reliable guidelines for optimal transducer placement during injections targeting compressive neuropathy at proximal and distal entrapment sites.

01 Jan 2025·Journal of Studies on Alcohol and Drugs

Trends of Buprenorphine Prescribing for Opioid Dependence Before and During the Early and Later Part of the COVID-19 Pandemic: A Study From a Large, Publicly Funded Opioid Agonist Treatment Service in India

Article

Author: Naik, Shalini S. ; Basu, Debasish ; Mattoo, Surendra K. ; Kaur, Simranjit ; Subodh, B. N. ; Ghosh, Abhishek

OBJECTIVE:

The COVID-19 pandemic has affected the availability of and access to medications for opioid dependence (OD). We examined the monthly trends in new buprenorphine/naloxone (BNX) treatment episodes, number of clinical visits for BNX, BNX dispensed per person, and BNX prescription over 56 months, which included the pre-pandemic period and the early and later parts of the pandemic (January 2017 to August 2022).

METHOD:

Research data were collected from the pharmacy database of a large publicly funded treatment center in India. A flexible, low-threshold service was adopted in April 2020 in response to the lockdown implemented on March 25, 2020. Change point analyses were performed to examine monthly trends visually and statistically. We used autoregressive integrated moving averages to forecast trends from April to August 2020 and March to August 2022, using January 2017 to March 2020 and March 2020 to February 2022 as training data sets.

RESULTS:

A total of 993 patients were started on BNX treatment; 40,452 BNX clinic attendances were made; 1,401,393 BNX tablets were dispensed; and 6,795 new patients with OD were registered. The observed data for clinic attendance for BNX was significantly lower than the projected estimates in April to August 2020; however, observed new treatment episodes and monthly BNX prescriptions were within the 95% projected estimates; BNX dispensed per person was significantly more than the projected estimate. In contrast, observed BNX prescription trends surpassed the upper limit of the 95% confidence interval in March to August 2022.

CONCLUSIONS:

A low-threshold and flexible-treatment service could mitigate the unintended consequences of pandemic-induced restrictions.

01 Dec 2024·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Spring and parachute approach for piroxicam dissolution; its phenomenological model on the thermodynamics of irreversible processes

Article

Author: Goto, Satoru ; Tsunoda, Chihiro ; Moritake, Kota ; Tsuchida, Tomohiro ; Kataoka, Hikaru ; Fujita, Momoko

Even though the spring and parachute approach for poorly water-soluble drug candidates effectively improves their dissolution curves with eutectic mixtures, deep eutectic solvents, solid dispersion polymers, and solid solutions, we cannot consider that its enabling factor in these pharmaceutical modifications was enough to be clarified. Based on our previous study that oxybuprocaine acts as a role of parachute generator for piroxicam, the present study explored a small-molecule parachute generator and found that propranolol, a β-adrenergic-blocking drug, has a parachute effect on the supersaturated state of piroxicam. In addition, changing the concentration of tetracaine and dibucaine to 10 mM and 2.5 mM also showed a parachute effect. These parachute generators control piroxicam's dissolved state kinetically by making the supersaturated state of piroxicam a steady state. However, as the piroxicam anhydrous crystals diminished and the piroxicam monohydrate crystals grew due to Ostwald ripening, it led to attenuating the supersaturated state. This finding advances the elucidation of the mechanism of the parachute effect of polymers.

1

News (Medical) associated with Benoxinate Hydrochloride

17 Oct 2023

·www.pharmaindustrial-india.com

C2 PHARMA Expands API Portfolio with Global Regulatory Access Ahead of CPhI Barcelona

C2 PHARMA is expanding its global access to its portfolio of active pharmaceutical ingredients (APIs) with new regulatory submissions and approvals. Earlier this year, they received a CEP for Cyclopentolate Hydrochloride and recently a C-DMF for Digoxin, demonstrating their commitment to becoming the leader in ophthalmic and niche APIs. “As we deepen our involvement in the Ophthalmic sector, our ability to successfully submit and secure numerous regulatory filings worldwide will enable us to better serve a truly global customer base in need of high-quality APIs.” states Andrew Badrot, CEO of C2 PHARMA. “I am very proud of what my team has been able to achieve and look forward to seeing how we bring this energy into the upcoming years with the pending launch of Oxybuprocaine (Benoxinate Hydrochloride) API in Q1-2024.” Along with the C-DMF and CEP approvals, the filings continue to grow across C2 PHARMA’s API portfolio. The most recent submissions include: A full list of products and their filings can be found here, with the R&D pipeline available here. As they progressively expand their portfolio of Ophthalmic APIs, C2 PHARMA has signed an agreement with an additional CMO partner, SMS Lifesciences. This strengthens their manufacturing network and accelerates their path towards bringing their R&D portfolio of Ophthalmic products to the commercial market. “We believe in forging long-term relationships with organizations that share our passion for quality, reliability, and excellence.” says Dr. James Lawler, General Manager of C2 PHARMA. “With the addition of SMS Lifesciences to our CMO network, we are confident in our ability to deliver exceptional pharmaceutical ingredients with the best cost-to-quality to meet the healthcare needs of patients worldwide.”

100 Deals associated with Benoxinate Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01768	Benoxinate Hydrochloride	D04AB03 S01HA02	DB00892

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Excessive tearing	Japan	Santen Pharmaceutical Co., Ltd.	26 Dec 1972
Anesthesia	Japan	Santen Pharmaceutical Co., Ltd.	07 Jun 1966

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02528123 (CTgov)	Not Applicable	Myopia	114	Small incision lenticule extraction+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+Tobramycin and dexamethasone+Ofloxacin	hmbhaihdyb(nsfvhljqqt) = xbceiltwmh ajwcdgygmu (fgtfllilui, 0.48) View more	-	23 Apr 2024
EURETINA2021	Not Applicable	-	42	Oxybuprocaine Hydrochloride	pdgmfaavxi(ardzjaiifi): P-Value = 0.029 View more	Positive	01 Sep 2021
				No Oxybuprocaine Hydrochloride
AAAAI2011	Not Applicable	-	67	Phenylephrine	zjncgdnvkv(liyhhvzjql) = dxzhokpaxk pnocufnuwq (xafbrbrrcd ) View more	Positive	01 Feb 2011
				Atropine	zjncgdnvkv(liyhhvzjql) = liprxoduzv pnocufnuwq (xafbrbrrcd ) View more
ARVO2006	Not Applicable	Ophthalmologic surgical procedures	50	Tetracaine/Oxybuprocaine	aaxajvierb(vwagmvhqhq) = ripvdxiyzr dquohwayzs (zjkhkflekl )	Positive	01 May 2006
				Oxybuprocaine	aaxajvierb(vwagmvhqhq) = ceedkshvil dquohwayzs (zjkhkflekl )